Compounds that modulate oxidative stress
View Patent ↗The present invention provides methods of identifying compounds that selectively induce an oxidative stress response in a biological sample. The present invention further provides methods of treating a subject having a disease associated with oxidative stress using compounds that selectively induce an oxidative stress response in the subject. The invention further provides methods of selectively inducing an oxidative stress response in a cell.
1. A method of identifying compounds that decrease oxidative stress by selectively inducing oxidative stress response in a biological sample, the method comprising:
(a) contacting the biological sample with one or more non-naturally occurring compounds;
(b) determining whether the one or more non-naturally occurring compounds induce an oxidative stress response in the biological sample, wherein induction of the oxidative stress response comprises inducing expression of at least the oxidative stress-responsive genes heme oxygenase 1 (HMOX 1), NAD(P)H:quinine oxidoreductase (NQO1), and thioredoxin reductase 1 (TXNRD1);
(c)(1) determining whether the one or more non-naturally occurring compounds activate a cellular stress response in the biological sample, wherein activation of the cellular stress response comprises inducing expression of at least the cellular stress genes Growth arrest and DNA-damage-inducible, alpha (GADD45A) and Heatshock 70 kDa protein 6 (HSPA6);
(c)(2) determining whether the one or more non-naturally occurring compounds activate nuclear factor-kappaB (NF-κB) in the biological sample, wherein activation of NF-κB is determined by measuring the induction of expression of intercellular adhesion molecule (ICAM-1); and
(d) selecting for the one or more non-naturally occurring compounds that induce the oxidative stress response but that do not significantly activate the cellular stress response in the biological sample and that do not significantly activate NF-κB in the biological sample.
2. The method of claim 1 , wherein step (d) further comprises selecting for the one or more non-naturally occurring compounds that induce expression of at least one oxidative stress-responsive gene in the biological sample by at least about two-fold as compared to an untreated biological sample, wherein the oxidative stress-response gene is selected from the group consisting of heme oxygenase 1 (HMOX1), NAD(P)H:quinine oxidoreductase (NQO1), and thioredoxin reductase 1 (TXNRD 1).
3. The method of claim 1 , wherein activation of NF-κB is measured by Western blotting, enzyme-linked immunosorbent assay (ELISA), electrophoretic mobility shift assay, or immunofluorescence.
4. The method of claim 1 , further comprising (c)(3) determining whether the one or more non-naturally occurring compounds increase reactive oxygen species (ROS) production in the biological sample, and wherein step (d) further comprises selecting for the one or more non-naturally occurring compounds that do not significantly increase ROS production in the biological sample.
5. The method of claim 4 , wherein ROS production is measured by contacting the biological sample with N-acetyl cysteine (NAC) and determining whether heme oxygenase 1 (HMOX1) expression is induced in the biological sample, thereby determining whether ROS production is increased in the biological sample.
6. The method of claim 1 , further comprising (c)(3) determining whether the one or more non-naturally occurring compounds decrease the level of glutathione in the biological sample, and wherein step (d) further comprises selecting for the one or more non-naturally occurring compounds that do not significantly decrease the level of glutathione in the biological sample.
7. The method of claim 1 , wherein induction of expression of the oxidative stress-responsive genes or the cellular stress genes is measured by mass spectroscopy, polymerase chain reaction (PCR), microarray hybridization, thermal cycle sequencing, capillary array sequencing, or solid phase sequencing.
8. The method of claim 1 , wherein expression of the oxidative stress-responsive genes or the cellular stress genes is measured by ELISA assay, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, or mass spectroscopy.
9. The method of claim 1 , further comprising comparing induction of expression of the oxidative stress-responsive gene by the one or more non-naturally occurring compounds to the induction of expression of the oxidative stress-responsive genes by Cobalt protoporphyrin IX (CoPP) and selecting for the one or more compounds having an EC50 less than or equal to the EC50 of CoPP.
10. The method of claim 1 , wherein the biological sample is a primary cell.
11. The method of claim 10 , wherein the cell is a mesenchymal stem cell, a fibroblast, an endothelial cell, or a vascular smooth muscle cell.
12. The method of claim 1 , wherein the biological sample is from a subject having a disease selected from the group consisting of fibrotic disease, neurodegenerative disease, cardiovascular disease, renal disease, inflammatory disease, liver disease, eye disease, thyroid disease, skin disease, viral infection, osteoporosis, and diabetes.